Hot Topic: Targeted Therapy
In this video, Anshu Giri, MD, MS, assistant professor of oncology at the Fox Chase Cancer Center, discusses:
- the effectiveness of recent FDA approvals, including trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) and olaparib (Lynparza; AstraZeneca, Merck);
- updates on clinical trials in triple negative breast cancer (EMBRACA, ASCENT, KEYNOTE 355);
- tactics in managing resistance to targeted therapies and adverse events;
- unmet needs in targeted therapies; and
- how resistance to targeted therapies may change the course of treatment.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.